T cell receptor for antigen induces linker for activation of T cell–dependent activation of a negative signaling complex involving Dok-2, SHIP-1, and Grb-2 by Dong, Shen et al.
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Improved knowledge of the molecular machine 
that directs TCR signaling provides insights to 
understand thymic selection, T cell response to 
antigen, peripheral tolerance, and homeostasis 
(1–4). The eff   ectiveness and harmlessness of 
these processes must be ensured by control 
mechanisms during TCR signal initiation, main-
tenance, and extinction. Each of these phases is, 
therefore, likely to be the resultant of the con-
trasting action of signaling circuits, a stratagem 
to accurately drive toward physiological out-
comes while avoiding damaging eff  ects. Dys-
regulation of one or more of these phases, 
resulting in alteration in signal magnitude and/
or duration, may promote immune deviation or 
break of tolerance (5, 6).
TCR signal is conveyed as a cascade of bio-
chemical modifi   cations controlling enzymatic 
activities, assembly, and localization of multi-
molecular complexes. Central to this cascade are 
adaptor proteins that connect signaling circuits 
by facilitating juxtaposition of eff  ectors  with 
their targets. Adaptors may contribute to pro-
mote and/or oppose TCR signaling (7–9). The 
membrane adaptor linker for activation of T 
cells (LAT) is prototypic of positive regulation 
(10), as TCR engagement induces Zap-70–
  mediated tyrosine phosphorylation of LAT 
which serves as an anchoring platform for com-
plexes activating major intracellular signaling 
pathways. However, recent data have suggested 
that LAT may also be a source of negative regu-
lation of antigen receptor signaling (11, 12). In 
addition, other adaptors such as downstream of 
kinase (Dok)-1, Dok-2, Gab-2, Grap, and LAX 
have been proposed to negatively regulate T cell 
activation (8, 13–16).
Dok adaptors constitute a family of six mem-
bers. Dok-1 (17, 18) and Dok-2 (or Dok-R/
FRIP) (19–21) are highly related in structure 
and are preferentially expressed, together with 
Dok-3, in hematopoietic cells (22). Whereas 
Dok-1 and Dok-2 are expressed in the T cell 
lineage (23, 24), B cells express Dok- 1 and 
Dok-3 (22). Mutant mice lacking Dok-1 exhib-
ited increased proliferation of thymocytes (25) 
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and B cells in vitro, the latter being caused by impaired 
FcγRIIB inhibitory function on B lymphocyte antigen 
  receptor (BCR) signaling (26). Studies in Dok-1−/−/Dok-2−/− 
double defi  cient mice showed that these adaptors exert redun-
dant (23, 24) yet not completely overlapping roles. Their 
  absence intensifi  ed development and homeostasis of hemato-
poietic cell precursors and mature cells, especially within the 
myeloid cell lineage and in response to cytokines (23, 24). With 
age, these mice developed chronic myelogenous leukemia 
(CML)–like disease and lymphomas (23, 24). Interestingly, 
Dok-1−/−/Dok-2−/− mice had a noticeably increased number 
of lymphocytes, and enhanced T cell proliferation was found 
in   mutant mice expressing low levels of Dok-2 in vitro (21). 
Conversely, mice overexpressing Dok-2 showed depressed 
T cell development (27). These data indicate that Dok-1 and 
Dok-2 are likely key regulators of homeostasis, activation, and 
proliferation in cells of hematopoietic origin.
Dok-1 and Dok-2 are typical docking proteins with an 
N-terminal module composed of tandem pleckstrin homol-
ogy (PH)-PTB domains followed by a region rich in binding 
motifs to Src homology (SH)2 and SH3 domains (20, 28). 
The precise stage at which Dok-1 and Dok-2 intervene in re-
ceptor signaling and the underlying mechanism of their action 
are not yet fully understood. Moreover, Dok-2 function in T 
cell activation is essentially unknown. Upon tyrosine phos-
phorylation, Dok-1 and Dok-2 have been reported to bind 
Ras–GTPase-activating protein, an inhibitor of Ras (17–19). 
Consistently, Dok-1 has been implicated in FcγRIIB-
  mediated decrease of BCR-induced Ras–extracellular signal-
regulated kinase (Erk)-1/2 activation (26, 29). Erk-1/2 
activation was also found to be attenuated in CD2-stimulated 
Jurkat T cells overexpressing Dok-1 (13) and increased in 
Dok-1−/−/Dok-2−/− myeloid cells stimulated by cytokines 
(23, 24). However, other studies performed with mutations 
in the binding sites of Ras–GTPase-activating protein have 
questioned its role in Erk-1/2 down-regulation via Dok-1 
and Dok-2 (30, 31). It has also been shown that Dok-1 and 
Dok-2 negatively control Akt/PKB activation (24, 30, 31).
We now report that in primary T cells, TCR stimulation 
results in early Dok-2 and Dok-1 tyrosine phosphorylation 
and their involvement in a multimolecular complex, which 
includes Src homology (SH)2 domain–containing inositol 
polyphosphate 5′-phosphatase (SHIP)-1, Grb-2, and LAT. 
We fi  nd that LAT and SHIP-1 are required for TCR-  induced 
Dok-2 tyrosine phosphorylation and propose that SHIP-1 
  allows anchoring of Dok-2 to LAT. Moreover, we show that 
Dok-2 and Dok-1 together negatively control activation of 
Zap-70 and Akt kinases, indicating that these adaptors act as 
attenuators of TCR signal at its initiation phase.
RESULTS
TCR/CD3 ligation induces Dok-2 and Dok-1 
tyrosine phosphorylation
We investigated Dok-2 activation after CD3 and/or CD28 
ligation. In normal T cells and transformed T cell lines, Dok-2 
appeared as a doublet of  53–56 kD (Fig. 1 A). Dok-2 was 
found weakly tyrosine phosphorylated in unstimulated CD4 
T cells, T cell blasts, a CD8 cytotoxic T cell clone (CTL) 
(Fig. 1 B), and Hut-78 cells (Fig. 2, A and B) but strongly 
phosphorylated in unstimulated J77 Jurkat cells (Fig. 2 A). 
TCR/CD3 stimulation led to substantial enhancement of 
Dok-2 phosphorylation in normal T cells (Fig. 1 B) and Hut-78 
cells (Fig. 2, A and B) but little augmentation in J77 cells 
(Fig. 2 A). Phospho–Dok-2 migrated diff  usely at and above 
55 kD (Fig. 1 B, brackets), presumably because of the high 
Figure 1.  TCR-induced tyrosine phosphorylation of Dok-2 in pri-
mary T cells. (A) Expression of the indicated proteins in lysates of differ-
ent cell types by immunoblot. (B) CD4+ and cytotoxic CD8+ T cells (CTL) 
were stimulated by CD3 cross-linking for 2 min at 37°C. T cell blasts were 
stimulated with Raji B cells (not expressing Dok-2) prepulsed or not with 
superantigens (SAgs) for 2 min. Dok-2 immunoprecipitates (IP) were ana-
lyzed by immunoblotting (WB) with anti-phosphotyrosine (pTyr) anti-
bodies. Brackets indicate the doublet form of Dok-2 migrating above 
IgH chains (*) that are visible when serum 157–2 was used for immuno-
precipitation. Ctr corresponds to protein A sepharose beads coated with 
anti–Dok-2 and without cell lysates. The bottom panels show reprobing 
with anti–Dok-2 mAbs. (C) Time course of CD3-mediated Dok-2 tyrosine 
phosphorylation in T cell blasts analyzed as in B. (D) T cells blasts were 
stimulated for 2 min with anti-CD28, 531 (B7−), 531-B7 (B7+) and SAgs-
pulsed 531-B7 cells. Cell lysates were divided, immunoprecipitated with 
anti–Dok-2 (H192) and anti–Vav-1 (H191), and analyzed for tyrosine 
phosphorylation. Bottom panels show reprobing with mAbs. These assays 
were performed with at least 10 donors.JEM VOL. 203, October 30, 2006  2511
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content of phosphorylatable tyrosine motifs (19). Importantly, 
superantigen (SAg)-pulsed Raji cells (antigen-presenting cells 
not expressing Dok-2) induced a substantial increase in Dok-2 
tyrosine phosphorylation in T cell blasts (Fig. 1 B, middle, 
lane 4), demonstrating that physiological TCR engagement 
induces activation of Dok-2. T cell contact with unpulsed 
Raji cells also induced weak Dok-2 phosphorylation (Fig. 1 B, 
middle, lane 3), possibly caused by engagement of a receptor 
distinct from TCR. Similar observations were made with un-
pulsed and SAg-pulsed autologous monocyte-derived den-
dritic cells (unpublished data). Dok-2 tyrosine phosphorylation 
was detected as early as 20 s after TCR stimulation, returning 
to background levels after 20–30 min (Fig. 1 C), a kinetics 
similar to that of Zap-70 activation and of other phosphopro-
teins (unpublished data).
When T cells were stimulated with anti-CD28 antibody 
or B7-1–expressing cells (531-B7), Dok-2 tyrosine phosphor-
ylation was only weakly induced above background level, 
whereas Vav-1, an eff  ector of CD28 signaling, was more effi   -
ciently tyrosine phosphorylated (Fig. 1 D). In contrast, SAg-
pulsed 531-B7 cells induced a substantial increment of Dok-2 
tyrosine phosphorylation, confi  rming that TCR is the stron-
ger inducer of this event (Fig. 1 D). Comprehensively, these 
data suggested that in normal T cells TCR engagement, rather 
than CD28, effi   ciently activated Dok-2. These data sharply 
contrasted with the behavior of Dok-1, the close Dok-2 ho-
mologue, which was reported to be inducibly phosphorylated 
in Jurkat cells by CD2 and CD28 but not by TCR triggering 
(13, 32, 33). One explanation for these opposite results may 
be the use of Jurkat cells, which also showed an unusually 
high basal phosphorylation of Dok-2 (Fig. 2 A). Jurkat cells 
lack expression of the lipid phosphatases, phosphatase and 
tensin homologue deleted in chromosome 10 (PTEN) and 
SHIP-1 (34), which causes dysregulated accumulation of 
phosphatidylinositol (PI) 3,4,5-trisphosphate and PI 3,4-
bisphosphate and basal activation of certain PH domain–
  containing proteins (34, 35). Consistent with this idea, in 
Hut-78 cells, which express both PTEN and SHIP-1 at levels 
comparable with primary T cells (34) (Fig. 1 A), TCR/CD3 
stimulation led to strong tyrosine phosphorylation of Dok-2 
(Fig. 2 A). Interestingly, Dok-1 was also tyrosine phosphory-
lated in Hut-78 after TCR/CD3 stimulation (Fig. 2 B). 
Moreover, similarly to Dok-2, its phosphorylation was 
  detected as early as 20 s after TCR triggering in primary 
T cells (Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20060650/DC1). Overall, these observations suggest 
a rapid activation of both Dok-2 and Dok-1 adaptors con-
comitant with TCR signal development, and may explain 
opposite results because of the use of Jurkat cells versus 
normal T cells.
TCR-induced assembly of a multimolecular complex 
including Dok-2, SHIP-1, and Grb-2 to LAT
Because TCR ligation induced a very rapid phosphorylation 
of Dok-2, we investigated whether it physically engaged with 
TCR signaling eff  ectors. T cell blasts were stimulated with 
anti-CD3 (Fig. 3 A, lanes 2 and 4) or Raji cells pulsed or not 
with SAgs (Fig. 3, last four lanes) and subjected to Dok-2 im-
munoprecipitation followed by antiphosphotyrosine immuno-
blot (Fig. 3 A, fi  rst panel). A major phosphoprotein of  145 
kD coprecipitated with Dok-2 after TCR stimulation, comi-
grated with phosphorylated SHIP-1 (lanes 2 and 6 with 4 and 8) 
and was identifi  ed as SHIP-1 by immunoblotting (Fig. 3 A, 
second panel). Kinetic assays further confi  rmed its rapid and 
relatively prolonged coprecipitation with Dok-2 after TCR 
engagement (Fig. S2, right, available at http://www.jem.org/
cgi/content/full/jem.20060650/DC1). This data is consistent 
with the reported Dok-2–SHIP-1 interaction upon SLAM 
stimulation (36). Similarly, tyrosine-phosphorylated SHIP-1 
was detected in Dok-1 immunoprecipitates upon TCR 
  stimulation (Fig. S3 A, available at http://www.jem.org/cgi/ 
content/full/jem.20060650/DC1). A weak Dok-2–SHIP-1 
association was seen in unstimulated cells and augmented after 
TCR stimulation (Fig. 3 A, anti–SHIP-1 immunoblot). 
  Conversely, Dok-2 protein and its phosphorylated form were 
found in SHIP-1 immunoprecipitates (Fig. 3 A, fourth panel 
and Fig. S3 B). In accordance with the described interaction 
of SHIP-1 with one SH3 domain of Grb-2 (37), substantial 
amounts of Grb-2 were constitutively associated with SHIP-1 
(Fig. 3 A, third panel, lanes 3, 4, 7, and 8) that slightly in-
creased upon TCR stimulation. A much lower amount of 
Grb-2 was also observed constitutively in Dok-2 immuno-
precipitates that weakly augmented after TCR triggering. 
This augmentation paralleled the increased binding of SHIP-1 
with Dok-2 and suggested stabilization of Grb-2–SHIP-1–
Dok-2. These fi  ndings were confi  rmed by probing Grb-2 
  immunoprecipitates with anti–SHIP-1 and anti–Dok-2 anti-
bodies (Fig. 3 B). As demonstrated in previous studies (10), 
Figure 2.  TCR-mediated Dok-2 and Dok-1 tyrosine phosphoryla-
tion in transformed T cell lines. (A) Jurkat J77 and Hut-78 cells were 
stimulated with anti-CD3 for 2 min. Dok-2 was immunoprecipitated 
(H192) and analyzed for tyrosine phosphorylation. The bottom panel 
shows reprobing with anti–Dok-2 Abs. (B) Hut-78 cells were stimulated 
and analyzed as in A. Half of cell lysates was precipitated with anti–Dok-1 
and anti–Dok-2 antibodies, respectively. Ctr, beads coated with antibodies. 
The two bottom panels show reprobing against the precipitated protein.2512  NEGATIVE SIGNALING IN T CELLS | Dong et al.
Grb-2 also bound to LAT upon TCR stimulation. Notewor-
thily, comparison of signal intensity of SHIP-1, Dok-2, and 
LAT coimmunoprecipitated with Grb-2 (Fig. 3 B, lanes 1 and 2) 
with their signals in the cell lysate (Fig. 3 B, lane 4) revealed 
the preferential association of SHIP-1 to Grb-2 with respect 
to Dok-2 and LAT, even after TCR stimulation.
Notably, pp36, pp47, and pp64 species were detected 
more strongly in SHIP-1 than Dok-2 immunoprecipitates, 
and an additional phosphoprotein of  116–118 kD was 
  associated with SHIP-1 (Fig. 3 A, arrows). The broad appear-
ance of the 36-kD molecular species was reminiscent of LAT. 
Indeed, immunoblotting of SHIP-1 immunoprecipitates with 
anti-LAT antibody confi  rmed that pp36 was LAT (Fig. 3 C). 
Moreover, tyrosine phosphorylation of SHIP-1 and copre-
cipitated LAT exhibited similar kinetic profi  les, suggesting 
a causal link between these events (Fig. S2, left). Reciprocally, 
SHIP-1 and Dok-2 were observed in LAT immunoprecipi-
tates upon TCR stimulation (unpublished data). Collectively, 
these data indicated that TCR triggering induced association 
of Dok-2–SHIP-1–Grb-2 to LAT, together with other phos-
phoproteins, suggesting that a bone fi  de negative signaling 
pathway is initiated coincidentally on the very same scaff  old 
(i.e., LAT) that directs positive signal propagation.
TCR-mediated Dok-2 tyrosine phosphorylation depends on 
LAT and SHIP-1
The association of Dok-2–SHIP-1–Grb-2 with LAT suggested 
that LAT may play a role in the activation of Dok-2 and 
SHIP-1. To answer this question, we inhibited LAT expres-
sion by small interfering (si)RNA and asked whether this mod-
ifi  ed SHIP-1 and Dok-2 phosphorylation. LAT expression was 
reduced in Hut-78 cells by 80–90% in comparison with cells 
transfected with irrelevant siRNA (siNeg or siScr), whereas 
expression of other proteins such as Dok-2, SHIP-1, PLC-γ1, 
Zap-70, and Vav-1 remained unaff  ected (Fig. 4, A and B and 
unpublished data). Upon TCR/CD3 stimulation, Hut-78 cells 
with reduced LAT expression exhibited impaired tyrosine phos-
phorylation of Dok-2 at 5 and 10 min (35–50% inhibition) 
as revealed with anti-pTyr351–Dok-2 antibody (Fig. 4 A). 
Consistent with previous fi  ndings in LAT-defi  cient Jurkat 
(38), activation of PLC-γ1, as estimated by anti-pTyr783–
PLC-γ1 antibody, was also partially (50–60%) aff  ected. Thus, 
when these data were compared with PLC-γ1 activation, the 
reduction of TCR-induced Dok-2 phosphorylation was sub-
stantial after LAT knockdown (80–90%). In contrast, TCR-
induced Zap-70 activation, known to occur upstream of 
LAT (39), was not aff  ected by LAT knockdown. Hut-78 cells 
with decreased LAT expression stimulated by CD3 also exhib-
ited inhibition of SHIP-1 tyrosine phosphorylation (38–56% 
  inhibition; Fig. 4 B). Importantly, impaired TCR-mediated 
phospho–Dok-2 was reproduced in primary T cells (30–47% 
reduction) in which LAT expression was inhibited by siRNA 
(50%) (Fig. 4 C) and with another siRNA against LAT in Hut-
78 cells (unpublished data). The stronger association of LAT 
with SHIP-1 than with Dok-2 (Fig. 3, A and C) suggested that 
Dok-2 tyrosine phosphorylation may depend on SHIP-1. 
Consistent with this hypothesis, we found that reduced expres-
sion of SHIP-1 (90% by siRNA) substantially aff  ected TCR-
mediated tyrosine phosphorylation of Dok-2 ( 60%; Fig. 
4 D) and of Dok-1 ( 40–50%; Fig. S4, available at http://
www.jem.org/cgi/content/full/jem.20060650/DC1). Con-
versely, double knockdown of Dok-2 and Dok-1 expression 
did not impair TCR-induced tyrosine phosphorylation of 
SHIP-1 (unpublished data). Collectively, these data supported 
Figure 3.  TCR-mediated assembly of a multimolecular complex in-
cluding Dok-2 SHIP-1, Grb-2 with LAT. (A) T cell blasts were stimulated 
with anti-CD3 (lanes 2 and 4) and Raji cells pulsed or not with SAgs (lanes 5–8) 
for 2 min. Dok-2 and SHIP-1 immunoprecipitates were analyzed for tyro-
sine phosphorylation. Bottom panels show IP reprobing with the indicated 
antibodies. White arrows indicate unidentifi  ed phosphoproteins coprecipi-
tating with SHIP-1 and more weakly with Dok-2. (B) Lysates from blasts 
stimulated with anti-CD3 or not were immunoprecipitated with anti–Grb-2 
antibodies (lanes 2 and 1). Beads coated with anti–Grb-2 alone (Ctr, lane 3) 
were used as a negative control. The lysate of unstimulated cells (15 μg 
proteins, lane 4) was used to provide a measure of SHIP-1, Dok-2, and LAT 
expression. The nitrocellulose membrane was cut in three parts and probed 
with mAbs against SHIP-1, Dok-2, and LAT, respectively. (Bottom blot) Grb-2 
expression in cell lysates that were immunoprecipitated. (C) SHIP-1 immuno-
precipitates of anti-CD3–stimulated blasts were probed with anti-LAT mAbs. 
The bottom panel shows that equal amounts of SHIP-1 were precipitated. 
A, B, and C assays were reproduced with three donors.JEM VOL. 203, October 30, 2006  2513
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the idea that TCR stimulation induces association of the Dok-
2–SHIP-1–Grb-2 complex with LAT followed by SHIP-1 
and Dok-2 tyrosine phosphorylation.
Knockdown of Dok-2 and Dok-1 enhances TCR-mediated 
IL-2 production and signaling
To assay the role of Dok-2 in TCR signaling, we measured 
TCR-mediated IL-2 secretion in Hut-78 cells knocked down 
for Dok-2 by siRNA. Inhibition of Dok-2 expression ( 90%; 
Fig. 5 A, middle blot) resulted in marginal or no increase in 
IL-2 secretion (Fig. 5 A, histograms). Similar to Dok-2, 
knockdown of Dok-1 alone ( 80%; Fig. 5 B, top blot) had 
minor or no impact on TCR-mediated IL-2 production (Fig. 
5 B, histograms). In contrast, combined inhibition of Dok-2 
and Dok-1 expression ( 90% and 80%, respectively) resulted 
in clear enhancement of TCR-induced IL-2 secretion in 
comparison with cells transfected with control siNeg or siScr 
RNA (Fig. 5, A and B). Collectively, these data indicated that 
Dok-1 and Dok-2 adaptors act together to negatively regu-
late TCR-mediated IL-2 gene activation. To examine the 
possibility of potential RNAi off  -target eff  ects, Dok-2 ex-
pression was restored in siDok-1/2–transfected cells, under the 
assumption that this would also substitute for Dok-1 function. 
To this aim, Hut-78 cells were cotransfected with a plasmid 
encoding human Dok-2 together with siDok-1/2 and IL-2 
promoter–dependent luciferase reporter plasmid. Substantial 
levels of Dok-2 expression were detected in transfected 
cells (Fig. 5 C, blot panel). Complementation of siDok-1/2–
transfected cells by Dok-2 cDNA alone was suffi   cient to re-
press TCR-mediated IL-2 gene expression and reverse the 
enhancement caused by siDok-1/2 (Fig. 5 C, histograms).
To begin understanding the molecular mechanism 
wherein the signaling cascade Dok-2 and Dok-1 infl  uence 
TCR-mediated activation, we analyzed these adaptor eff  ects 
on Akt/PKB and Erk-1/2. These kinases have been found to 
be more eff  ectively activated upon cytokine stimulation of 
Dok-1−/−/Dok-2−/− myeloid cells (23, 24). We found that 
TCR-induced Erk-1/2 activation was poorly enhanced in 
Hut-78 doubly knocked down for Dok-2 and Dok-1 expres-
sion (unpublished data). However, double knockdown re-
sulted in marked basal and prolonged TCR-mediated Akt 
activation as detected with an anti–pSer473-Akt antibody 
compared with siNeg-transfected Hut-78 cells (Fig. 6 A). 
These data are consistent with Dok1 and Dok-2 adaptors 
negatively controlling Akt activation (24) and extend this 
  eff  ect to the TCR signaling machinery.
Interestingly, by examining other TCR signal eff  ectors in 
Hut-78 knocked down for Dok-2 and Dok-1, we consis-
tently detected an increased activation of Zap-70 in stimu-
lated cells as revealed by an anti-pTyr319–Zap-70 antibody 
(Fig. 6 A). This eff  ect was particularly observed at early time 
Figure 4.  TCR-mediated Dok-2 tyrosine phosphorylation depends 
on LAT and SHIP-1 expression. (A) Hut-78 cells were transfected with 
control siNeg and siLAT RNA. 24 h later, cells were stimulated with soluble 
anti-CD3 for the indicated times. Cell lysates were analyzed by immuno-
blotting for LAT knockdown effi  ciency (left panels) and activation of Dok-2, 
PLC-γ1 and Zap-70 with phospho-specifi  c antibodies (right panels). White 
lines indicate that intervening lanes have been spliced out. (B) Hut-78 cells 
were transfected and stimulated as in A. SHIP-1 immunoprecipitates were 
analyzed for tyrosine phosphorylation and reprobed with anti–SHIP-1 
mAbs. LAT knockdown effi  ciency was 90% (not depicted). (C) Peripheral 
blood lymphocytes were electroporated by nucleofection with siNeg and 
siLAT (1.5 μM) and CD3-stimulated 48 h later. Cell lysates were analyzed 
for Dok-2 tyrosine phosphorylation and LAT knockdown effi  ciency as in A. 
Similar data were obtained with two other donors. (D) Hut-78 cells 
were transfected with control siScr and siSHIP-1. Cell lysates were analyzed 
for CD3-induced Dok-2 tyrosine phosphorylation and SHIP-1 knockdown 
efficiency as in A. The indicated values have been normalized to the 
  protein loading in blots performed with anti–Vav-1, Dok-2 (A, C, and D) and 
SHIP-1 antibodies (B).2514  NEGATIVE SIGNALING IN T CELLS | Dong et al.
points after TCR stimulation (and at 20 s; unpublished data). 
Enhanced Akt and Zap-70 activations were more pronounced 
in double than in single knockdown of Dok-2 and Dok-1 
(unpublished data). Moreover, these eff  ects appeared to be 
selective since p38 kinase activation was not enhanced and 
even decreased in unstimulated cells (Fig. 6 A). Alterations of 
the TCR-induced tyrosine phosphorylation profi  le were ob-
served upon knockdown of Dok-2 and Dok-1. In particular, 
proteins of  36, 70, and 76 kD were more phosphorylated 
after TCR ligation (Fig. S5, http://www.jem.org/cgi/ 
content/full/jem.20060650/DC1). In accordance with the 
enhancement of Zap-70 activation, LAT and SLP-76, as well 
as PLC-γ1, were found to be more phosphorylated (Y191, 
Y128 and Y783, respectively) (Fig. 6 B). Importantly, this 
was also the case for CD3ζ and its coprecipitated partner 
Zap-70 (Fig. 6 C). Overall, these data support the existence 
of a molecular mechanism that fi  nely regulates TCR signal 
initiation by a negative feedback loop involving Dok-2 and 
Dok-1 recruitment, via SHIP-1, on LAT which reduces 
Zap-70 activation.
DISCUSSION
In this work we demonstrate that the adaptors Dok-2 and 
Dok-1 are key eff  ectors of a TCR proximal negative feed-
back control mechanism. This notion stands on two novel sets 
of fi  ndings. First, TCR ligation induced rapid binding to LAT 
and tyrosine phosphorylation of Dok-2 and Dok-1 in com-
plex with SHIP-1. The latter appeared to act as a carrier for 
these adaptors. Second, reduced expression of both Dok-2 
and Dok-1 by siRNA resulted in increased amplitude and 
Figure 5.  Dok-2 and Dok-1 negatively control TCR-mediated IL-2 
production. (A and B) Hut-78 cells were transfected with the indicated 
siRNA and, 24 h later, stimulated with immobilized anti-CD3 for 4 h. IL-2 
secretion was determined by ELISA. Blots show inhibition of Dok-1 and 
Dok-2 expression by siDok-1 and siDok-2 (lanes 2) or a single siRNA 
(lanes 3). (C) Hut-78 cells were transfected as with siRNA. After 24 h, they 
were cotransfected with the same siRNA together with phIL-2–Luc and 
the indicated quantities of pCMV5–Dok-2 (Dok-2, μg) or empty vector 
(Dok-2, −) to adjust for equal amounts of total DNA. Luciferase activity 
was measured after 6h of stimulation with immobilized anti-CD3. The 
blot shows Dok-2 reexpressed upon cotransfection of siDok-1, si Dok-2, 
and pCMV5-Dok-2. In A, B, and C, IL-2 gene activation was normalized to 
PMA/A23187 stimulation. Histogram bars correspond to 0.48 (hatched), 
0.12 (empty), 0.06 (gray), and 0.03 (black) μg/ml of anti-CD3.JEM VOL. 203, October 30, 2006  2515
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duration of TCR-induced Zap-70 activation and of other 
  tyrosine-phosphorylated proteins and basal- and TCR-induced 
Akt activation with consequent augmentation of IL-2 gene 
expression. Individual knockdown of Dok-2 or Dok-1 had 
minimal or undetectable eff  ects, suggesting that they exert re-
dundant negative signaling functions, in agreement with pre-
vious data in cells of myeloid origin (23, 24). Comprehensively, 
our data demonstrate that LAT physically integrates, in appar-
ent temporal coincidence, two opposing signals. A dominant 
signal promotes TCR-controlled activation (10), whereas the 
second, implicating Dok adaptors and probably other modu-
latory proteins (8), attenuates it. We propose that this type of 
mechanism may contribute to control the TCR activation 
threshold (“signal gatekeeper”) and/or to shape TCR signal 
form in intensity and duration (“signal tailoring”).
Triggering of BCR or FcεRI was also reported to in-
duce tyrosine phosphorylation of Dok adaptors and SHIP-1 
(22, 29, 40). In light of our results, it will be of   interest 
to determine whether antigen receptors use similar or dis-
tinct stratagems to recruit and activate Dok-dependent neg-
ative signals.
Previous studies in Jurkat cells showed that CD2 and 
CD28 receptors, but not TCR, induced potent tyrosine 
phosphorylation of Dok-1 and Dok-2, suggesting their par-
ticipation in costimulatory signaling pathways (13, 32, 33; 
unpublished data). Our present results do not support this 
view in primary T cells because little or no tyrosine phos-
phorylation of Dok-2 was observed upon CD28 ligation. A 
possible explanation for this diff  erence may be that in Jurkat 
cells, similar to Akt, activation of PH domain–containing 
Dok-1, 2 may be deregulated because of altered phosphati-
dylinositol metabolism, consequent to the absence of PTEN 
and SHIP-1 (34, 41).
In accordance with previous data (37), SHIP-1 was con-
stitutively bound to Grb-2. We also found some basal SHIP-1–
Dok-2 association that likely resulted from weak basal tyrosine 
phosphorylation of both proteins (Figs. 1, 3, and S2). How-
ever, TCR stimulation led to a marked increase in SHIP-1 
and Dok-2 phosphorylations and their prolonged association. 
In support of phosphotyrosine-dependent interactions, Dok-2 
and Dok-1 PTB domains were shown to bind to tyrosine-
phosphorylated SHIP-1 (29, 36). We examined the reciprocal 
role of Dok-1, Dok-2 and SHIP-1 in their activation by 
knocking down their expression in Hut-78 cells. Knock-
down of SHIP-1 revealed that it primarily controls TCR-
  induced tyrosine phosphorylation of Dok-2 and Dok-1. 
Conversely, a decrease in TCR-mediated SHIP-1 tyrosine 
phosphorylation was not observed in T cells knocked down 
for Dok-2 and Dok-1 (unpublished data). Moreover, knock-
down of LAT resulted in a marked alteration of TCR-mediated 
SHIP-1, Dok-2, and Dok-1 tyrosine phosphorylation. Alto-
gether, our data support the idea that in T cells, SHIP-1 me-
diates recruitment and activation of Dok-2 and Dok-1 to 
LAT. In accordance with a SHIP-1 “carrier” function, SHIP-
1–defi  cient thymocytes do not exhibit Dok-2 tyrosine phos-
phorylation upon SLAM stimulation (36). A similar defect 
was observed for Dok-1 in SHIP-1–defi  cient B cells stimu-
lated by BCR and FcγRIIB (29). How SHIP-1 is connected 
to LAT remains to be determined as we did not observe 
binding of the SHIP-1 SH2 domain to LAT in glutathione 
S-transferase pull-down assays (unpublished data). LAT con-
tains several Grb-2 binding sites, and recent reports have 
  indirectly suggested that LAT may be a source of negative 
signaling (11, 12). Thus, one scenario would involve recruit-
ment to LAT of Grb-2/SHIP-1–Dok adaptors in direct com-
petition with other positive signaling complexes containing 
Grb-2. It remains possible that other players may control 
Dok-2, Dok-1, and SHIP-1 recruitment/tyrosine phosphor-
ylation because the latter was not completely abolished in 
LAT knocked down cells. A candidate may be, for instance, 
the inhibitory membrane adaptor LAX possessing several 
Grb-2 binding sites (42). This possibility may, however, be 
less likely because the inhibition of SHIP-1 and Dok-2 phos-
phorylation was comparable to that of PLCγ-1 in LAT 
knocked down T cells. Overall, our fi  ndings support the 
  notion that LAT drives concomitantly negative and positive 
signals with potential consequences on T cell fate.
Figure 6.  Knockdown of Dok-2 and Dok-1 results in enhanced TCR-
mediated tyrosine phosphorylations and Akt kinase activation. Hut-78 
cells were transfected with siDok-1 and siDok-2, control siRNAs, and stim-
ulated with anti-CD3 for the indicated times. (A and B) Cell lysates were 
analyzed by immunoblotting with anti–phospho-specifi  c antibodies. (C) CD3ζ 
was immunoprecipitated (8.73 antibodies) and analyzed for tyrosine phos-
phorylation and loading (448 antibodies). A, B, and C are representative of 
three experiments. Knockdown of Dok-2 and Dok-1 expression was  90% 
and 70–80%, respectively (not depicted). Numbers indicate increases in the 
phosphorylation level after normalization to protein loading in Vav-1 
(A and B) and CD3ζ (C) blots.2516  NEGATIVE SIGNALING IN T CELLS | Dong et al.
Our data also reveal a surprising negative control exerted 
by Dok-2 and Dok-1 on TCR-induced activation of Zap-70 
and on substrates whose phosphorylation depend on Zap-70 
(e.g., LAT, SLP-76, and PLC-γ1) (Fig. 6, A and B). Because 
TCR-induced tyrosine phosphorylation of Dok-2 and Dok-1 
is very rapid (as early as 20 s), these data imply that these 
adaptors counteract TCR signal development at its initiation 
step. This fi  nding can be related to a work proposing that 
Dok-2 binds to c-Src and attenuates its activity upon epidermal 
growth factor stimulation by recruiting Csk, the Src   kinase 
family inhibitor kinase (31). Interestingly, Dok-1 was also re-
cently demonstrated to control Csk localization at the plasma 
membrane and inhibit Src activation in a Csk-dependent 
manner upon platelet-derived growth factor stimulation (43). 
Similarly, in B cells, Dok-3 may dampen B cell activation 
through Csk association in addition to its binding to SHIP-1 
(22, 44). Optimal activation of Zap-70 is tightly dependent 
on Lck binding and catalytic activity (45). Thus, the negative 
control of Dok-2 and Dok-1 on Zap-70 may be explained by 
their upstream control on Lck. In accordance with this prop-
osition, we observed increased TCR-mediated tyrosine 
phosphorylation of CD3ζ upon knockdown of Dok-2 and 
Dok-1. However, the fact that knockdown of Dok-2 and 
Dok-1 did not dramatically aff  ect these events suggests that 
these adaptors act as attenuators of TCR signal. This would 
also explain why we did not succeed in reproducibly de-
tecting an increase in Zap-70 activation in siLAT-treated 
cells. In fact, LAT knockdown did not mimic the eff  ect of 
Dok-2 and Dok-1 knockdown on Zap-70. Indeed, a 1.5–2-
fold increase in TCR-induced Zap-70 activation was de-
tected, whereas Dok-2 and Dok-1 expressions were markedly 
decreased (90–80%). In contrast, LAT knockdown led to 
the clear reduced, but not abolished, Dok-2 and Dok-1 
phosphorylation. The remaining phosphorylated Dok may 
still negatively control TCR-induced Zap-70 activation. 
Moreover, we observed a correlation between the levels of 
residual LAT expression and T cell activation. For instance, 
PLC-γ1 phosphorylation and IL-2 production were still no-
ticeable (though strongly decreased) when residual LAT ex-
pression was around 10–15% or when the strength of TCR 
engagement was high (unpublished data).
A substantial enhancement of basal and prolonged TCR-
induced activation of Akt was observed in Hut-78 cells 
knocked down for Dok-2 and Dok-1, in agreement with Akt 
activation increase in Dok-1−/−/Dok-2−/− mice (24). Our 
data of Dok-2 and Dok-1 knockdown in Hut-78 cells suggest 
that enhanced Akt activation may be a consequence of Zap-70 
or, for the same matter, Src-PTK up-regulation. Indeed, 
  although the precise mechanism of this regulation has yet to 
be determined, decreased Akt activation has been described 
upon overexpression of Dok-2 and epidermal growth factor 
receptor stimulation (31). What is then the role of SHIP-1 in 
this mechanism? One possibility is that SHIP-1 needs to be 
correctly localized in the TCR signalosome to exert, together 
with Dok-bound partners, its phosphatase activity on PI 
3,4,5-trisphosphate, and contribute to this negative feedback 
loop. Indeed, SHIP−/− and Dok-2−/−/Dok-1−/− mice pre-
sent close phenotypes characterized by enhanced Akt activa-
tion, survival, and expansion of myeloid cells (23, 24, 46). 
The negative control of SHIP-1 on Akt activation has also 
been demonstrated in T cells with an inducible expression 
system (41). However, because SHIP-1 appears to be manda-
tory for Dok-1 and Dok-2 recruitment (and phosphorylation), 
one appealing possibility is that SHIP-1 serves mostly as a 
  carrier to facilitate the action of Dok proteins on signal 
  attenuation. Since Akt plays an important role in T cell 
survival, IL-2 gene activation, and cell cycle progression 
(47, 48), Dok-2 and Dok-1 are therefore likely to play a role 
in these processes.
Several mechanisms that counteract signal onset and 
propagation have been proposed. These “negative” signals 
can emanate from membrane receptors (e.g., CD5, CTLA-4) 
or from phosphatases that constantly oppose activating 
phosphorylations on signaling components, or are activated 
as a consequence of receptor engagement (e.g., SHP-1, 
SHP-2). Our data show that Dok-2 and Dok-1 are involved 
in an early negative feedback mechanism acting through 
LAT. This molecular device may represent a mechanism to 
adapt toward homeostatic/tonic TCR signal intensity and/or 
attenuate incoming TCR signal. T cells indeed appear to 
require control mechanisms of their signaling machinery 
for maintaining a basal tonic signal and repress gene expres-
sion (49) while avoiding response to self-antigen and allow-
ing survival and proliferative homeostasis (3, 4). Such a 
control implicating Dok-2 and Dok-1 is suggested by their 
slight basal tyrosine phosphorylation that we observed in 
primary T cells. Thus, Dok-1, 2 may play a gatekeeper 
function in setting the threshold of T cell activation and 
contributing to maintain peripheral T cell tolerance and 
homeostasis. Alternatively, but not exclusively, by shaping 
the intensity and duration of antigen-induced signals, Dok-2 
and Dok-1 may infl  uence naive T cell diff  erentiation and 
eff  ector functions.
MATERIALS AND METHODS
Cells and cultures. Hut-78, Jurkat J77cl20 T cell, and Raji B cell lym-
phoma were cultured in RPMI 1640 containing 10% heat-inactivated 
FCS, 2 mM l-glutamine, penicillin, and streptomycin. L cells expressing 
DRB1*0101 (531) and B7-1 (531-B7) were cultured in complete DMEM 
with 50 μg/ml hygromycin B (33). Primary T cells were maintained 
overnight in complete RPMI supplemented with 1 mM sodium pyruvate 
and nonessential amino acids (GIBCO BRL). Blood samples from healthy 
donors were obtained from Etablissement Français du Sang (EFS), Paris, 
France in accordance with a convention signed between the Institut Pas-
teur and EFS. Human peripheral blood mononuclear cells (PBMCs) were 
isolated by Ficoll density gradient, and peripheral blood lymphocytes 
were obtained after PBMC adhesion (10 × 106/ml) in RPMI 2% FCS for 
1 h at 37°C. Phytohemagglutinin/IL-2 T cell blasts were harvested at days 
6–13 of culture established with PBMCs (3 × 106/ml) that were stimu-
lated by phytohemagglutinin (2 μg/ml) for 2–3 d and then expanded with 
IL-2 (50 ng/ml; Chiron). Flow cytometric analysis showed that >97% 
cells were CD3+ and 95% CD28+ at days 6–8. Naive CD4 T cells were 
purifi  ed by negative selection (90–98%) and an AutoMACS apparatus 
(Miltenyi Biotec). The human CD8+ CTL clone specifi  c of CMV has 
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Antibodies. Mouse mAbs were against CD3 (UCHT1; Serotec), CD28 
(CD28.2; Immunotech), Vav-1 (Vav-30; a gift from J. Griffi   n, Dana Farber 
Cancer Institute, Boston, MA), Dok-2 (E10; Santa-Cruz Biotechnology, 
Inc.), LAT (2E9; Upstate), SHIP-1 (P1C1; Santa-Cruz Biotechnology, Inc.), 
PTEN (A2B1; Santa-Cruz Biotechnology, Inc.), a cocktail of antiphospho-
tyrosine mAbs including 4G10 (Upstate), PY20 (Transduction Lab.), and 
PY99 (Santa-Cruz Biotechnology, Inc.). Rabbit antibodies were against 
Dok-2 (H-192 [Santa-Cruz Biotechnology, Inc.] and serum 157–2[36]), 
Dok-1 (13602 [Abcam] and serum A.V.[22]), SHIP-1 165.1 3′ (22), CD3ζ 
chain (8.73 and 448 sera[51]), Grb2 (C23) and Vav-1 (H211) (Santa-Cruz 
Biotechnology, Inc.), phospho-Tyr351-Dok-2, Ser473-Akt, Tyr319Zap-70, 
Tyr783-PLC-γ1, and Thr180-Tyr182-p38 kinase (Cell Signaling). mAb 
against phosphorylated SLP-76 Y128 was from BD Biosciences. Goat anti–
mouse IgG and IgG1 were from Southern Biotechnology Associates, Inc.
siRNA duplexes. siRNA duplexes containing 19 nucleotides with 2 
thymidine 3′ overhangs were purchased from Eurogentec, Qiagen, and 
Proligo-Sigma. The sequences were as follows: 5′-G  A  A  U  G  C  U  G  C  A  C  C  C-
G  C  U  A  C  A  -3′ for siDok-2, 5′-G  G  U  C  A  U  G  U  U  C  U  C  U  U  U  C  G  A  G  -3′ for 
siDok-1, 5′-G  C  U  A  A  G  U  G  C  U  U  U  A  C  G  A  A  C  A  -3′ for siSHIP-1, 5′-A  C  G  C-
A  U  G  U  A  C  A  C  A  C  U  C  G  C  G  -3′ for a randomly Dok-2 scrambled sequence 
(siScr), and two negative control RNA duplexes (siNeg) from Qiagen and 
Ambion, respectively. SiRNA used for silencing LAT gene expression was 
from Santa-Cruz Biotechnology, Inc.
Cell transfections. To achieve maximal RNAi, Hut-78 cells (12 × 106/0.4 ml) 
were electroporated two to three times at 24 h intervals with siRNAs 
(200–300 nM) at 260 V, 950 μF (Bio Rad Laboratories). Cells were  harvested 
24–48 h after the last electroporation. For IL-2 gene activation, Hut-78 cells 
were fi  rst transfected with siDok-1/2 or siScr (300 nM). After 24 h, these 
cells were cotransfected with the same siRNA together with pCMV5 en-
coding HA-tagged human Dok-2 (19) and IL-2 promoter luciferase reporter 
plasmid (phIL-2-Luc, 10 μg) at 230 V, 950 μF. The total amount of DNA 
was adjusted to 25 μg with empty vector. Luciferase activity was measured 
in triplicate 24 h after the second transfection using a microplate lumino-
meter (LB96V, Berthold; PerkinElmer). Primary T cells (6 × 106) were 
transfected with siRNA (1–1.5 μM) by nucleofection (Amaxa) according to 
the supplier’s instructions and incubated in p24-well plates in complete 
RPMI medium for 48 h.
Cell stimulation, immunoprecipitation, and immunoblots. Primary 
T cells (6–10 × 106) were stimulated in RPMI (1.5 × 108/ml) at a ratio of 5:1 
with APC (5 × 107/ml) previously pulsed for 1 h with a mixture of superanti-
gens (Staphylococcal enterotoxin A, B, C3 at 0.2 μg/ml; Toxin Technology) 
at 37°C. Jurkat, Hut-78, and primary T cells (1.2 × 108/ml) were stimulated 
by cross-linking of CD3 (5 μg/ml) with anti-IgG1 antibodies (20 μg/ml) as 
previously described (33) or with soluble anti-CD3 (5 μg/ml). CD28 stimula-
tion with antibodies was performed by cross-linking (10 μg/ml) and with 531 
cells expressing B7.1 (33). Cells were lysed at 4°C for 10 min in buff  er (20 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM MgCl
2, 1 mM EGTA, 50 mM NaF, 
10 mM Na
4P
2O
7, 1 mM Na3VO4) containing 1% NP-40 and 1% n-dodecyl-
β-d-maltoside (Sigma-Aldrich) and inhibitors of proteases. Lysates were cleared 
by centrifugation and equal amounts of protein, determined by Bradford assay 
(Bio Rad Laboratories), were immunoprecipitated for 2 h at 4°C with the indi-
cated antibodies preadsorbed to protein A– or protein G–Sepharose (Amersham 
Biosciences). Immunoprecipitates and whole cell lysates (15 μg proteins) were 
separated by SDS-PAGE and transferred to nitrocellulose membrane. Immuno-
blots were analyzed by enhanced chemiluminescence (Western Lightning; 
PerkinElmer) or by near-infrared fl  uorescence using secondary goat anti–mouse 
or goat anti–rabbit IgG labeled with AlexaFluor 680 (Invitrogen) and IRDye 
800 (Rockland Immunochemicals), respectively. Signals were acquired and 
quantifi  ed with a Kodak Image Station 440 cf or an Odyssey scanner and the 
Odyssey 1.2 software (Li-Cor Biosciences), or after scanning fi  lms in the linear 
range of exposure. Phosphoprotein signals and RNAi effi   ciency were normal-
ized to the protein loading charge evaluated by immunoblot.
IL-2 production. SiRNA-treated Hut-78 cells were stimulated in triplicate 
in p96-well round plates with immobilized anti-CD3 for 4 h at 37°C. Goat 
anti–mouse IgG (4 μg/ml) were coated in wells in PBS overnight at 4°C and 
washed twice. UCHT1 was added at diff  erent concentrations for 1 h at 37°C 
in PBS and washed twice. After saturation of wells in RPMI 10% FCS, T cells 
were added (5 × 105/ml). TCR-independent activation was induced with 
PMA (5 ng/ml) and A23187 (0.1 μg/ml). IL-2 production was measured 
from 4 h cell culture supernatants by ELISA (R&D Systems). A sample of 
siRNA-treated cells was kept to check for RNAi effi   ciency by immunoblot.
Online supplemental material. In addition to Dok-2, Dok-1 was tyro-
sine phosphorylated (Fig. S1) and interacted with SHIP-1 (Fig. S3) after 
TCR stimulation of primary T cells. TCR-mediated Dok-1 tyrosine phos-
phorylation was dependent on SHIP-1 expression in Hut-78 cells (Fig. S4). 
Kinetics of TCR-induced SHIP-1–LAT and Dok-2–SHIP-1 complex for-
mation are shown in Fig. S2. Fig. S5 shows TCR-induced tyrosine phos-
phorylation profi  le in Hut-78 cells knocked down for Dok-2 and Dok-1 
expression in which enhanced phosphorylation of  36, 70, and 76 kD pro-
teins was detected. Online supplemental material is available at http://www.
jem.org/cgi/content/full/jem.20060650/DC1.
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